The UK Health and Safety Executive (HSE) has announced significant changes to the approval status of certain biocidal active substances, impacting the Northern Ireland market. As of 24 January 2024, the EU Biocidal Products Regulation (EU BPR) has led to the non-approval of specific active substance/product type combinations, necessitating the phase-out of affected biocidal products in Northern Ireland by 23 December 2025.
Impact on Northern Ireland's Biocidal Market
The recent EU BPR decisions, communicated by the UK HSE, have far-reaching implications for suppliers and users of biocidal products in Northern Ireland. Key substances affected include silver adsorbed on silicon dioxide, used as a nanomaterial in product type 9, and p-[(Diiodomethyl)sulphonyl]toluene, applicable in product types 6, 7, 9, and 10. These substances can no longer be supplied after 23 December 2025 or used after 23 June 2026. Suppliers must manage their stocks to ensure compliance with these deadlines.
Actions Required for Compliance
Biocidal product suppliers must apply for EU BPR product authorisation by 1 June 2026 to continue supplying products containing the reaction products of boric acid with didecylamine and ethylene oxide in product type 8. New products cannot be introduced to the NI market until authorisation is granted. Active substance suppliers must demonstrate technical equivalence for their manufacturing sources to obtain product authorisation.
Uses and Risks of Affected Chemicals
The affected chemicals have diverse applications and associated risks. Silver adsorbed on silicon dioxide is commonly used for its antimicrobial properties in various consumer products. However, its nanoscale form raises concerns about potential environmental and health impacts. Similarly, p-[(Diiodomethyl)sulphonyl]toluene is used as a preservative and antimicrobial agent, but its use is restricted due to potential health risks.
Industry Response and Next Steps
Industry stakeholders are urged to assess the impact of these regulatory changes and take necessary actions to mitigate potential disruptions. The HSE encourages those aware of disproportionate negative impacts to contact them for further discussion. Companies must ensure compliance with the new regulations to avoid penalties and maintain market access.
